A commercial vendor received two AAV samples, one serotype 5 (AAV5) and one serotype 9 (AAV9). The two samples were generated ...

Triple transfection technology has propelled commercial launch of rAAV-based gene therapy for eye-disease patients across the US. Despite newer and more efficient systems emerging, this approach ...

Despite these technical challenges, the benefits of baculovirus-based manufacturing have made this approach a popular commercial alternative to the standard ‘triple-transfection’ AAV strategy.